Citation: | ZHAO Qiyao, LI Jiaoyue, WEN Yalu, YUAN Ruyue, ZHANG Ye, HU Chaoyue, ZHANG Li, YANG Xiaohui. Visual analysis of traditional Chinese medicine in the treatment of diabetic cardiomyopathy based on CiteSpace[J]. Chinese Journal of General Practice, 2023, 21(12): 2064-2067. doi: 10.16766/j.cnki.issn.1674-4152.003291 |
[1] |
SUN H, SAEEDI P, KARURANGA S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pr, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
|
[2] |
高霜, 张艳丽, 吴姗姗, 等. 2型糖尿病患者的糖尿病痛苦现状调查及影响因素分析[J]. 中华全科医学, 2020, 18(12): 2136-2139.
GAO S, ZHANG Y L, WU S S, et al. Investigation and analysis of influencing factors of diabetes distress in type 2 diabetic patients[J]. Chinese Journal of General Practice, 2020, 18(12): 2136-2139.
|
[3] |
DILLMANN W H. Diabetic cardiomyopathy[J]. Circ Res, 2019, 124(8): 1160-1162. doi: 10.1161/CIRCRESAHA.118.314665
|
[4] |
MUTAZA G, VIRK H, KHALID M, et al. Diabetic cardiomyopathy: a comprehensive updated review[J]. Prog Cardiovasc Dis, 2019, 62(4): 315-326. doi: 10.1016/j.pcad.2019.03.003
|
[5] |
马振旺, 姜德友, 袁星星, 等. 白藜芦醇通过Mst1/Sirt3信号通路介导的细胞自噬改善糖尿病心肌损伤的机制研究[J]. 海南医学院学报, 2022, 28(4): 251-257.
MA Z W, JIANG D Y, YUAN X X, et al. Mechanism of resveratrol on autophagy mediated by Mst1/Sirt3 signaling pathway in diabetic cardiomyopathy[J]. Journal of Hainan Medical University, 2022, 28(4): 251-257.
|
[6] |
马振旺, 姜德友, 胡丙成, 等. 白藜芦醇通过HSF1介导的铁死亡改善糖尿病心肌细胞损伤的机制研究[J]. 海南医学院学报, 2022, 28(6): 406-411, 419.
MA Z W, JIANG D Y, HU B C, et al. Resveratrol ameliorates diabetic myocardial injury through HSF1-mediated ferroptosis[J]. Journal of Hainan Medical University, 2022, 28(6): 406-411, 419.
|
[7] |
何流, 金智生, 张花治, 等. 红芪多糖对db/db小鼠糖尿病心肌病心肌组织氧化应激的影响[J]. 中华中医药杂志, 2019, 34(6): 2445-2449.
HE L, JIN Z S, ZHANG H Z, et al. Effects of hedysarum polybotys saccharide on controlling oxidative stress in myocardial tissue of diabetic cardiomyopathy in db/db mice[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2019, 34(6): 2445-2449.
|
[8] |
钱秋海, 倪青, 杨文军. 糖尿病心肌病病证结合诊疗指南(2021-12-31)[J]. 世界中医药, 2022, 17(12): 1641-1653. doi: 10.3969/j.issn.1673-7202.2022.12.001
QIAN Q H, NI Q, YANG W J. Combination of Disease and Syndrome Guidelines for Diabetes Cardiomyopathy (2021-12-31)[J]. World Chinese Medicine, 2022, 17(12): 1641-1653. doi: 10.3969/j.issn.1673-7202.2022.12.001
|
[9] |
温雅璐, 吴宏辉, 黄举凯, 等. 自发性2型糖尿病KKAy小鼠心脏结构和功能改变实验研究[J]. 现代中西医结合杂志, 2023, 32(1): 31-37.
WEN Y L, WU H H, HUANG J K, et al. Changes in cardiac structure and function of spontaneously type 2 diabetic KKAy mice[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2023, 32(1): 31-37.
|
[10] |
曾奇虎, 刘孟楠, 李小林, 等. 基于PI3K/AKT1/FoxO3a信号通路探讨蛭龙活血通瘀胶囊对糖尿病心肌病大鼠的影响[J]. 中药材, 2023, 46(1): 197-201.
ZENG Q H, LIU M N, LI X L, et al. Effects of Zhilong Huoxue Tongyu Capsules on diabetic cardiomyopathy rats based on PI3K/AKT1/FoxO3a signaling pathway[J]. Journal of Chinese Medicinal Materials, 2023, 46(1): 197-201.
|
[11] |
TAN Y, ZHANG Z, ZHENG C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence[J]. Nat Rev Cardiol, 2020, 17(9): 585-607. doi: 10.1038/s41569-020-0339-2
|
[12] |
KARWI Q G, HO K L, PHERWANI S, et al. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches[J]. Cardiovasc Res, 2022, 118(3): 686-715. doi: 10.1093/cvr/cvab120
|
[13] |
SUN Y, DING S. NLRP3 Inflammasome in diabetic cardiomyopathy and exercise intervention[J]. Int J Mol Sci, 2021, 22(24): 13228. doi: 10.3390/ijms222413228
|
[14] |
杨嫒萍, 张磊, 李炜, 等. 黄芪甲苷对糖尿病心肌病小鼠的治疗作用及其机制[J]. 山东医药, 2022, 62(23): 19-24.
YANG A P, ZHANG L, LI W, et al. Therapeutic effect of astragaloside Ⅳ on diabetic cardiomyopathy mice and its mechanism[J]. Shandong Medical Journal, 2022, 62(23): 19-24.
|
[15] |
李莺莺, 王卫, 王欣, 等. 生脉散对2型糖尿病大鼠心肌氧化应激的作用及miR-19a、PPARα、CD36因子的影响[J]. 中华中医药杂志, 2022, 37(4): 2218-2222.
LI Y Y, WANG W, WANG X, et al. Effects of Shengmai Power on myocardial oxidative stress and miR-19a, PPARα, CD36 in type 2 diabetic rats[J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2022, 37(4): 2218-2222.
|
[16] |
CHEN Y, HUA Y, LI X, et al. Distinct types of cell death and the implication in diabetic cardiomyopathy[J]. Front Pharmacol, 2020, 11: 42. doi: 10.3389/fphar.2020.00042
|
[17] |
CUI X, WANG Y, LIU H, et al. The molecular mechanisms of defective copper metabolism in diabetic cardiomyopathy[J]. Oxid Med Cell Longev, 2022, 2022: 5418376. DOI: 10.1155/2022/5418376.
|
[18] |
MADONNA R, MOSCATO S, CUFARO M C, et al. Empagliflozin inhibits excessive autophagy through the AMPK/GSK3beta signaling pathway in diabetic cardiomyopathy[J]. Cardiovasc Res, 2023, 119(5): 1175-1189.
|
[19] |
叶婷, 陈晶, 马国庆, 等. 黄芪多糖对糖尿病心肌病大鼠自噬的调控机制研究[J]. 时珍国医国药, 2022, 33(2): 312-316.
YE T, CHEN J, MA G Q, et al. Regulation mechanism of astragalus polysaccharides on autophagy in diabetic cardiomyopathy rats[J]. Lishizhen Medicine and Materia Medica Research, 2022, 33(2): 312-316.
|